CN106309923A - Medicine compound for increasing safety of compound sealwort injection - Google Patents
Medicine compound for increasing safety of compound sealwort injection Download PDFInfo
- Publication number
- CN106309923A CN106309923A CN201610968061.6A CN201610968061A CN106309923A CN 106309923 A CN106309923 A CN 106309923A CN 201610968061 A CN201610968061 A CN 201610968061A CN 106309923 A CN106309923 A CN 106309923A
- Authority
- CN
- China
- Prior art keywords
- injection
- safety
- pharmaceutical composition
- extract
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicine compound for increasing the safety of a compound sealwort injection. The medicine compound is an injection medicine compound which is made from sealwort extract, wolfberry extract, platycodon extract and polyvinyl acetate. According to the invention, a cosolvent with higher safety and more obvious fluxing effect is used for replacing the cosolvent polysorbate 80 with potential safety hazards and influences on product quality in the compound sealwort injection, the safety of polyvinyl acetate is higher than the safety of polysorbate 80 and the dosage is less, so that the probability and risk of untoward effects of the medicine can be reduced and the safety of clinical medication can be increased.
Description
Technical field
The invention belongs to pharmaceutical technology field, in particular it relates to a kind of medicine improving compound Polygonatum injection safety
Compositions.
Background technology
Compound Polygonatum injection standard is recorded in health drug standard promulgated by the ministries or commissions of the Central Government (Traditional Chinese medicine historical preparation), crude drug be Rhizoma Polygonati,
Fructus Lycii, Radix Platycodonis, belong to Chinese medicine injection.There is promoting blood circulation to restore menstrual flow, effect of stasis-dispelling and pain-killing.Be clinically used for treat dysmenorrhea, amenorrhea,
Injury from falling down, rheumatic arthralgia etc..
In China in wide clinical application for many years, clinical efficacy has obtained the good of doctor and patient to compound Polygonatum injection
Comment.But in recent years, the Reporting of harms of Chinese medicine injection clinical practice is on the rise, and have impact on and has Chinese Medicine characteristic
The development of Chinese medicine injection.Domestic experts and scholars have carried out numerous studies to the untoward reaction of Chinese medicine injection, and it is reported by document
The generation of untoward reaction has very with the cosolvent polyoxyethylene sorbitan monoleate (Tween 80) of the existence potential safety hazard of addition in Chinese medicine injection
Big relation.Due to Chinese medicine injection complicated component, in storage and autoclaving process, easily occur that solute separates out and affects clear
The problems such as lightness, solution ph are decreased obviously, therefore add polyoxyethylene sorbitan monoleate (Tween 80) in such injection and make hydrotropy
Agent, the solubilization-aid effect adding other cosolvents is the most inconspicuous.But polyoxyethylene sorbitan monoleate (Tween 80) is immature due to process for refining,
Storage and autoclaving process are easily become sour, causes impurity content high, it is difficult to reaching injection standard, polyoxyethylene sorbitan monoleate (is told
Temperature 80) inherently there is stronger hemolytic and anaphylaxis, apply add in injection occur untoward reaction probability and
Risk.It addition, Chinese medicine injection there is also, in sterilizing and storage process itself, the problem that solution ph is decreased obviously, and poly-Pyrusussuriensis
Ester 80 (Tween 80) the most easily becomes sour, and more accelerates the decline of the pH value of medicinal liquid.The compound Polygonatum injection of domestic production at present
In also add polyoxyethylene sorbitan monoleate (Tween 80) and make cosolvent, be faced with same problem.
In view of the foregoing, the poly-mountain that safety is more preferable, poor stability replaced by the more obvious cosolvent of solubilization-aid effect is found
Pear ester 80 (Tween 80) is this injection urgent problem.
Summary of the invention
The technical problem to be solved is to provide that a kind of safety is more preferable, solubilization-aid effect more obviously improves compound recipe
The pharmaceutical composition of Rhizoma Polygonati injection safety.
The present invention solves above-mentioned technical problem and be the technical scheme is that a kind of raising compound Polygonatum injection safety
Pharmaceutical composition, mainly by Rhizoma Polygonati extract, Fructus Lycii extract, Radix Platycodonis extract and polyvinyl acetate make for note
Penetrate pharmaceutical composition.
Specifically, the consumption of polyvinyl acetate is 0.005g～5.0g/100ml；The consumption of polyvinyl acetate is preferred
For 0.05g～1.0g/100ml.
Aforementioned pharmaceutical compositions also including, polyoxyethylene sorbitan monoleate, polyvinyl acetate and polyoxyethylene sorbitan monoleate press different proportion connection
Cooperation cosolvent, the usage ratio of polyvinyl acetate and polyoxyethylene sorbitan monoleate be 0.005g～5.0g/100ml:0.001g～
2.0g/100ml。
Described medicine composition dosage form is injection, powder pin or lyophilizing.
A kind of preparation method improving compound Polygonatum injection safety pharmaceutical composition, comprises the steps:
(1) compound Polygonatum injection raw medicinal material Rhizoma Polygonati 100g, Fructus Lycii 100g, Radix Platycodonis 100g, cosolvent 2.0g；
(2) Rhizoma Polygonati, Fructus Lycii boiling secondary, each 2 hours, collecting decoction, add ethanol filtering and concentrating, add 3 times amount
Water, is sufficiently stirred for, cold preservation 48 hours, filters, and filtrate reduced in volume to relative density is about 1.15, and medicinal liquid is standby；
(3) Radix Platycodonis boiling secondary, each 1 hour, collecting decoction, filter, concentrated filtrate, let cool, add ethanol and make to contain
Amount of alcohol is 65%, stands overnight, and filters, and filtrate reduced in volume to relative density is 1.20, adds ethanol and makes and containing amount of alcohol is
70%, stand overnight, filter, it is 1.30 that filtrate is concentrated into relative density, adds 3 times amount water, is sufficiently stirred for, cold preservation 48 hours, filter
Crossing, it is 1.15 that filtrate is concentrated into relative density,
(4) merge with above-mentioned all medicinal liquids, add 2 times amount water, be sufficiently stirred for, cold preservation 24 hours, filter, filtrate adds hydrotropy
Agent and water for injection are configured to 1000ml solution, stir evenly, and the relative density of above-mentioned each filtrate is relative density when 80 DEG C；
(5) by sodium hydroxide solution regulation solution ph to 6.5-8.5；
(6) filter, fill, sterilizing, to obtain final product.
For the method that the present invention is better achieved, further, in described step (1), cosolvent is by polyvinyl acetate
Ester forms with polyoxyethylene sorbitan monoleate, and wherein the content of polyvinyl acetate is 0.005g～2.0g, and surplus is polyoxyethylene sorbitan monoleate.
For the method that the present invention is better achieved, further, in described step (2), the mistake of ethanol filtering and concentrating is added
Cheng Wei, first filters to get filtrate, and filtrate reduced in volume to relative density is 1.27～1.30, lets cool, and adds ethanol and makes and containing amount of alcohol is
65%, stand overnight, filter, decompression filtrate recycling ethanol to be concentrated into relative density be 1.30.
For the method that the present invention is better achieved, further, in described step (3), filtrate is concentrated into relative density
It is 1.25～1.30.
For the method that the present invention is better achieved, further, in described step (5), the sodium hydroxide solution of use
Mass percent be 20%.
For the method that the present invention is better achieved, further, in described step (6), solution uses microporous filter membrane mistake
Filter.
The present invention, by substantial amounts of experimentation, finds a kind of Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester
(Solutol ) it is the preferable substitute products of polyoxyethylene sorbitan monoleate.Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester
(Solutol ) recorded in European Pharmacopoeia (EP5.5), Deutscher Arzneibucs and British Pharmacopoeia, can be used for ejection preparation
Solubilizing agent.The pharmacological toxicology experimental data of document report shows that its toxicity is significantly lower than polyoxyethylene sorbitan monoleate (Tween 80).Additionally I
Be experimental studies have found that by substantial amounts of, reach Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester during identical solubilization-aid effect
(Solutol ) amount ratio polyoxyethylene sorbitan monoleate (Tween 80) low, more improve Drug safety.
The pharmacological toxicology experimental data of document report shows Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester (Solutol) safety higher than polyoxyethylene sorbitan monoleate (Tween 80), its toxicity (sees below significantly lower than polyoxyethylene sorbitan monoleate (Tween 80)
Table 1-3).(0.5g/100ml) Polyethylene Glycol (PEG) ten dihydroxy using equivalent in compound Polygonatum injection respectively is stearic
Acid esters (Solutol) and polyoxyethylene sorbitan monoleate (Tween 80), safety experiment comparative study result shows, uses equivalent
(0.5g/100ml) Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester (Solutol) group is in hemolytic, stimulation
Property, anaphylaxis and the toxicity aspect the most substantially ratio such as reduce blood pressure use polyoxyethylene sorbitan monoleate (Tween 80) to organize low, by this
There is probability and the risk of untoward reaction in the bright compound Polygonatum injection that considerably reduces in clinical practice, improves clinical application
Safety.
To sum up, the invention has the beneficial effects as follows: a kind of safety of offer is more preferable, the more obvious cosolvent of solubilization-aid effect is replaced
Compound Polygonatum injection exists potential safety hazard and affects the cosolvent polyoxyethylene sorbitan monoleate (Tween 80) of product quality；Polyethylene Glycol
(PEG) 12-hydroxy stearic acid ester (Solutol) safety is higher than polyoxyethylene sorbitan monoleate (Tween 80) and also consumption
Lower, reduce probability and the risk of medicine generation untoward reaction, improve the safety of clinical application.
Detailed description of the invention
Embodiment 1
Preparation method: Rhizoma Polygonati, Fructus Lycii boiling secondary, each 2 hours, collecting decoction, filter, filtrate reduced in volume
Being 1.27～1.30 (80 DEG C) to relative density, let cool, add ethanol and make containing amount of alcohol to be 65%, stand overnight, filtering, filtrate subtracts
Push back receipts ethanol and to be concentrated into relative density be 1.30 (80 DEG C), add 3 times amount water, be sufficiently stirred for, cold preservation 48 hours, filter, filter
Liquid is evaporated to relative density and is about 1.15 (80 DEG C), and medicinal liquid is standby；Radix Platycodonis boiling secondary, each 1 hour, merges and decocts
Liquid, filters, and it is 1.25～1.30 (80 DEG C) that filtrate is concentrated into relative density, lets cool, and adds ethanol and makes containing amount of alcohol to be 65%, stands
Overnight, filtering, filtrate reduced in volume to relative density is 1.20 (80 DEG C), adds ethanol and makes containing amount of alcohol to be 70%, stands overnight,
Filtering, it is 1.30 (80 DEG C) that filtrate is concentrated into relative density, adds 3 times amount water, is sufficiently stirred for, cold preservation 48 hours, filters, and filtrate is dense
Being reduced to relative density is 1.15 (80 DEG C), merges with above-mentioned medicinal liquid, adds 2 times amount water, be sufficiently stirred for, cold preservation 24 hours, filters, filter
Liquid adds Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester (Solutol) make cosolvent and water for injection is configured to
1000ml solution.Stir evenly.By 20% sodium hydroxide solution regulation solution ph to 6.5-8.5.By above-mentioned solution through microporous filter membrane
Filter.Fill, sterilizing, to obtain final product.
Embodiment 2
Preparation method: Rhizoma Polygonati, Fructus Lycii boiling secondary, each 2 hours, collecting decoction, filter, filtrate reduced in volume
Being 1.27～1.30 (80 DEG C) to relative density, let cool, add ethanol and make containing amount of alcohol to be 65%, stand overnight, filtering, filtrate subtracts
Push back receipts ethanol and to be concentrated into relative density be 1.30 (80 DEG C), add 3 times amount water, be sufficiently stirred for, cold preservation 48 hours, filter, filter
Liquid is evaporated to relative density and is about 1.15 (80 DEG C), and medicinal liquid is standby；Radix Platycodonis boiling secondary, each 1 hour, merges and decocts
Liquid, filters, and it is 1.25～1.30 (80 DEG C) that filtrate is concentrated into relative density, lets cool, and adds ethanol and makes containing amount of alcohol to be 65%, stands
Overnight, filtering, filtrate reduced in volume to relative density is 1.20 (80 DEG C), adds ethanol and makes containing amount of alcohol to be 70%, stands overnight,
Filtering, it is 1.30 (80 DEG C) that filtrate is concentrated into relative density, adds 3 times amount water, is sufficiently stirred for, cold preservation 48 hours, filters, and filtrate is dense
Being reduced to relative density is 1.15 (80 DEG C), merges with above-mentioned medicinal liquid, adds 2 times amount water, be sufficiently stirred for, cold preservation 24 hours, filters, filter
Liquid adds Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester (Solutol) make cosolvent and injection with tween 80
It is configured to 1000ml solution with water.Stir evenly.By 20% sodium hydroxide solution regulation solution ph to 6.5-8.5.By above-mentioned solution
Filter through microporous filter membrane.Fill, sterilizing, to obtain final product.
Embodiment 3
Preparation method: Rhizoma Polygonati, Fructus Lycii boiling secondary, each 2 hours, collecting decoction, filter, filtrate reduced in volume
Being 1.27～1.30 (80 DEG C) to relative density, let cool, add ethanol and make containing amount of alcohol to be 65%, stand overnight, filtering, filtrate subtracts
Push back receipts ethanol and to be concentrated into relative density be 1.30 (80 DEG C), add 3 times amount water, be sufficiently stirred for, cold preservation 48 hours, filter, filter
Liquid is evaporated to relative density and is about 1.15 (80 DEG C), and medicinal liquid is standby；Radix Platycodonis boiling secondary, each 1 hour, merges and decocts
Liquid, filters, and it is 1.25～1.30 (80 DEG C) that filtrate is concentrated into relative density, lets cool, and adds ethanol and makes containing amount of alcohol to be 65%, stands
Overnight, filtering, filtrate reduced in volume to relative density is 1.20 (80 DEG C), adds ethanol and makes containing amount of alcohol to be 70%, stands overnight,
Filtering, it is 1.30 (80 DEG C) that filtrate is concentrated into relative density, adds 3 times amount water, is sufficiently stirred for, cold preservation 48 hours, filters, and filtrate is dense
Being reduced to relative density is 1.15 (80 DEG C), merges with above-mentioned medicinal liquid, adds 2 times amount water, be sufficiently stirred for, cold preservation 24 hours, filters, filter
Liquid adds Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester (Solutol) make cosolvent and water for injection is configured to
Solution.Stir evenly.By 20% sodium hydroxide solution regulation solution ph to 6.5-8.5.Above-mentioned solution is filtered through microporous filter membrane.Point
Dress up 1000, lyophilization, to obtain final product.
Embodiment 4:
The Rhizoma Polygonati extract of the present invention, Fructus Lycii extract, Radix Platycodonis extract and Polyethylene Glycol (PEG) ten dihydroxy are stearic
Acid esters (Solutol) the injection pharmaceutical composition made can be achieved through the following technical solutions:
(1) compound Polygonatum injection raw medicinal material Rhizoma Polygonati 100g, Fructus Lycii 100g, Radix Platycodonis 100g, Polyethylene Glycol (PEG) ten
Dihydroxystearic acid ester (Solutol)2.0g；
(2) Rhizoma Polygonati, Fructus Lycii boiling secondary, each 2 hours, collecting decoction, filter, filtrate reduced in volume is to relatively
Density is 1.27～1.30 (80 DEG C), lets cool, and adds ethanol and makes containing amount of alcohol to be 65%, stands overnight, and filters, and filtrate decompression reclaims
Ethanol to be concentrated into relative density be 1.30 (80 DEG C), adds 3 times amount water, is sufficiently stirred for, and cold preservation 48 hours filters, filtrate decompression
Being concentrated into relative density and be about 1.15 (80 DEG C), medicinal liquid is standby；Radix Platycodonis boiling secondary, each 1 hour, collecting decoction, filter
Crossing, it is 1.25～1.30 (80 DEG C) that filtrate is concentrated into relative density, lets cool, and adds ethanol and makes containing amount of alcohol to be 65%, stands overnight,
Filtering, filtrate reduced in volume to relative density is 1.20 (80 DEG C), adds ethanol and makes containing amount of alcohol to be 70%, stands overnight, and filters,
It is 1.30 (80 DEG C) that filtrate is concentrated into relative density, adds 3 times amount water, is sufficiently stirred for, cold preservation 48 hours, filters, and filtrate is concentrated into
Relative density is 1.15 (80 DEG C), merges with above-mentioned medicinal liquid, adds 2 times amount water, is sufficiently stirred for, cold preservation 24 hours, filters, and filtrate adds
Enter Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester (Solutol) make cosolvent and water for injection is configured to
1000ml solution.Stir evenly.
(3) by 20% sodium hydroxide solution regulation solution ph to 6.5-8.5.
(4) above-mentioned solution is filtered through microporous filter membrane.
(5) fill, sterilizing, to obtain final product.
In the present invention, cosolvent can be polyvinyl acetate, and its consumption is any in 0.005g～5.0g/100ml
Value, such as 0.005g/100ml, 0.01g/100ml, 0.05g/100ml, 1.0g/100ml, 5.0g/100ml etc.；Cosolvent also may be used
To be made up of with polyoxyethylene sorbitan monoleate polyvinyl acetate, its usage ratio is 0.005g～5.0g/100ml:0.001g～2.0g/
100ml。
Claims (6)
1. the pharmaceutical composition improving compound Polygonatum injection safety, it is characterised in that main by Rhizoma Polygonati extract, Chinese holly
The injection pharmaceutical composition that Fructus Lycii extract, Radix Platycodonis extract and polyvinyl acetate are made.
The pharmaceutical composition of raising compound Polygonatum injection safety the most according to claim 1, it is characterised in that every
100ml solution is containing being equivalent to the Rhizoma Polygonati extract of 5-15g Rhizoma Polygonati medical material, the Fructus Lycii extract of 5-15g Fructus Lycii medical material, 5-
The Radix Platycodonis extract of 15g Radix Platycodonis medical material, Rhizoma Polygonati, Fructus Lycii, the usage ratio of Radix Platycodonis medical material are 1:1:1.
The pharmaceutical composition of raising compound Polygonatum injection safety the most according to claim 1, it is characterised in that described
The consumption of polyvinyl acetate is 0.005g～5.0g/100ml.
The pharmaceutical composition of raising compound Polygonatum injection safety the most according to claim 3, it is characterised in that described
The consumption of polyvinyl acetate is 0.05g～1.0g/100ml.
The pharmaceutical composition of raising compound Polygonatum injection safety the most according to claim 1, it is characterised in that described
Also including polyoxyethylene sorbitan monoleate in pharmaceutical composition, polyvinyl acetate and polyoxyethylene sorbitan monoleate are combined by different proportion and are made cosolvent,
Polyvinyl acetate is 0.005g～5.0g/100ml:0.001g～2.0g/100ml with the usage ratio of polyoxyethylene sorbitan monoleate.
6., according to the pharmaceutical composition improving compound Polygonatum injection safety described in claim 1 to 5 any one, it is special
Levying and be, described medicine composition dosage form is injection, powder pin or lyophilizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610968061.6A CN106309923A (en) | 2016-11-06 | 2016-11-06 | Medicine compound for increasing safety of compound sealwort injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610968061.6A CN106309923A (en) | 2016-11-06 | 2016-11-06 | Medicine compound for increasing safety of compound sealwort injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106309923A true CN106309923A (en) | 2017-01-11 |
Family
ID=57816485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610968061.6A Withdrawn CN106309923A (en) | 2016-11-06 | 2016-11-06 | Medicine compound for increasing safety of compound sealwort injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106309923A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108159261A (en) * | 2018-01-25 | 2018-06-15 | 四川吉晟生物医药有限公司 | A kind of Chinese medicine composition for preventing and treating menstrual period syndrome and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105079067A (en) * | 2015-09-23 | 2015-11-25 | 成都艾比科生物科技有限公司 | Pharmaceutical composition for improving safety of compound gastrodin injection |
| CN105079107A (en) * | 2015-09-23 | 2015-11-25 | 成都艾比科生物科技有限公司 | Medicine composite of honeysuckle hydrochloric acid extract injection and preparation method thereof |
-
2016
- 2016-11-06 CN CN201610968061.6A patent/CN106309923A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105079067A (en) * | 2015-09-23 | 2015-11-25 | 成都艾比科生物科技有限公司 | Pharmaceutical composition for improving safety of compound gastrodin injection |
| CN105079107A (en) * | 2015-09-23 | 2015-11-25 | 成都艾比科生物科技有限公司 | Medicine composite of honeysuckle hydrochloric acid extract injection and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108159261A (en) * | 2018-01-25 | 2018-06-15 | 四川吉晟生物医药有限公司 | A kind of Chinese medicine composition for preventing and treating menstrual period syndrome and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105079067A (en) | Pharmaceutical composition for improving safety of compound gastrodin injection | |
| CN105106111A (en) | Safe medicine composition for compound gastrodin injection and preparation method of safe medicine composition | |
| CN1226940C (en) | Royal jelly composition with improved sleep function | |
| CN106309923A (en) | Medicine compound for increasing safety of compound sealwort injection | |
| CN105902580A (en) | Preparing method for pharmaceutical composition capable of improving safety of compound ginkgo biloba injection | |
| CN106389319A (en) | Preparation method of pharmaceutical composition capable of improving safety of compound herba andrographis injection | |
| CN105920117A (en) | Pharmaceutical composition capable of improving safety of compound radix polygoni multiflori injection | |
| CN105079107A (en) | Medicine composite of honeysuckle hydrochloric acid extract injection and preparation method thereof | |
| CN106389317A (en) | Preparation method of pharmaceutical composition for improving safety of compound puerarin injection | |
| CN104491007A (en) | Preparation method of fructus schisandrae chinensis soft capsule | |
| CN106309904A (en) | Preparation method for medicine compound for increasing safety of compound schisandra chinensis injection | |
| CN106309569A (en) | Medicine compound for increasing safety of compound codonopsis pilosula injection | |
| CN106389323A (en) | Pharmaceutical composition for improving safety of compound Fructus Schisandrae Chinensis injection | |
| CN106389318A (en) | Pharmaceutical composition for improving safety of compound puerarin injection | |
| CN105998096A (en) | Pharmaceutical composition capable of improving safety of compound gingko biloba injection | |
| CN106474206A (en) | A kind of preparation method improving compound recipe Dinggongteng Injection safety pharmaceutical composition | |
| CN106309524A (en) | Medicine compound for increasing safety of compound folium ginkgo injection | |
| CN106344504A (en) | Pharmaceutical composition capable of improving safety of compound andrographis injection | |
| CN106361814A (en) | Preparation method of pharmaceutical composition for improving safety of compound ginseng injection | |
| CN106344505A (en) | Pharmaceutical composition capable of improving safety of compound obtuseleaf erycibe stem injection | |
| CN106389322A (en) | Pharmaceutical composition for improving safety of compound Herba Artemisiae Scopariae injection | |
| CN106361826A (en) | Preparation method of pharmaceutical composition for improving safety of compound radix codonopsis injection solution | |
| CN106361793A (en) | Preparation method of pharmaceutical composition for improving safety of compound herba artemisiae scopariae injection solution | |
| CN106420866A (en) | Preparation method of pharmaceutical composition capable of improving safety of compound folium ginkgo injection | |
| CN105998113A (en) | Pharmaceutical composition for improving safety of compound radix bupleuri injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170111 |